Independently from FLT3 status, patients with an expression level above 1.173 for IL2RA at B-ALL diagnosis time showed a diminished survival time of 6.35 months (P = 0.012) and an increased risk of 3.73 times (95% CI: 1.3–10.72; P = 0.024) for relapse/death among the studied population. The gene discussed is IL2RA; the disease is acute lymphoblastic leukemia.